Review



rabbit recombinant anti zeb2 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Proteintech rabbit recombinant anti zeb2 antibody
    Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of <t>ZEB2</t> in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.
    Rabbit Recombinant Anti Zeb2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 93 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit recombinant anti zeb2 antibody/product/Proteintech
    Average 95 stars, based on 93 article reviews
    rabbit recombinant anti zeb2 antibody - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Upregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition."

    Article Title: Upregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition.

    Journal: Non-coding RNA research

    doi: 10.1016/j.ncrna.2025.06.001

    Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of ZEB2 in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.
    Figure Legend Snippet: Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of ZEB2 in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.

    Techniques Used: Expressing, Binding Assay, Sequencing, Quantitative RT-PCR, Transfection, Control, Western Blot, Infection



    Similar Products

    rabbit recombinant anti zeb2 antibody  (Proteintech)
    95
    Proteintech rabbit recombinant anti zeb2 antibody
    Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of <t>ZEB2</t> in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.
    Rabbit Recombinant Anti Zeb2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit recombinant anti zeb2 antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    rabbit recombinant anti zeb2 antibody - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of ZEB2 in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.

    Journal: Non-coding RNA research

    Article Title: Upregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition.

    doi: 10.1016/j.ncrna.2025.06.001

    Figure Lengend Snippet: Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of ZEB2 in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.

    Article Snippet: A mouse monoclonal anti-GAPDH mAb (1:5000 dilution, HRP-60004, Proteintech, Rosemont, IL, USA), rabbit monoclonal anti-cyclin B1 mAb (1:1000 dilution, #12231, Cell Signaling Technology, Danvers, MA, USA), and rabbit recombinant anti-ZEB2 antibody (1:3000 dilution, 82020-1-RR, Proteintech) were used.

    Techniques: Expressing, Binding Assay, Sequencing, Quantitative RT-PCR, Transfection, Control, Western Blot, Infection